Overview

Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)

Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sclnow Biotechnology Co., Ltd.
Treatments:
Azacitidine
Decitabine